Amendment 01 RFQ2 NAD.pdf

This document is an Amendment to Solicitation HT9402-25-Q-9303 issued by the Defense Health Agency on June 5, 2025. The amendment specifically modifies the file name of the Ustekinumab NDC Price List, removing "Centocor" from the original file name at the request of POD on June 3, 2025. The change will be reflected in the SAM.gov description and the TCon meeting agenda.

The amendment is part of a broader Request for Quotation (RFQ) for pharmaceutical agents to be reviewed by the DoD Pharmacy and Therapeutics (P&T) Committee in August 2025. The solicitation involves the selection of pharmaceutical agents for the DoD Uniform Formulary, with potential award of Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP). The specific drug under consideration in this amendment is ustekinumab, categorized under Targeted Immunomodulatory Biologics - IL-23.